RecruitingNot ApplicableNCT06091566

Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD)

Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfunction (BD) - An Early Feasibility Study


Sponsor

InnoCon Medical

Enrollment

20 participants

Start Date

Jan 12, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

UCon is a medical device for treatment of the symptoms of overactive bladder (OAB) and bowel dysfunction (BD). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder/bowel musculature e.g., suppress undesired bladder/bowel activity to relieve the symptoms of the patient. This clinical investigation is designed as a single-arm, prospective, multi-centre, and early feasibility study.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria9

  • Participant is female
  • Participant is ≥ 18 years of age.
  • Participant is diagnosed with OAB or BD.
  • OAB: Urinary urgency usually with one or more of the following:
  • i. Urinary urgency incontinence (≥1 per/week). ii. Urinary frequency (≥8 voiding/day without polyuria). iii. Nocturia (≥2 voiding/night without nocturnal polyuria).
  • BD: One or more of the following:
  • i. Faecal urgency (≥3 urgencies pr. week) together with registration of urgency in St. Mark´s and a St. Mark´s score ≥9.
  • ii. Faecal incontinence (urge/passive) (≥1 per/week).
  • Participant is able to communicate, provide feedback, understand and follow instructions during the course of the investigation, including using the device at home.

Exclusion Criteria10

  • Participant is medically unstable (acute illness or complication of a chronic condition, apart from the OAB or BD, that might affect the participants´ participation in the investigation).
  • Participant has an active infection in the genital area.
  • Participant has an implanted pacemaker, implantable drug pump or other active medical devices (any medical device that uses electrical energy or other sources of power to make it function).
  • Participant is pregnant, nursing or planning a pregnancy (to be confirmed with a negative pregnancy test). Women of childbearing potential must maintain effective contraception during the clinical investigation.
  • Participant is enrolled or planning to enrol in another conflicting clinical investigation or was enrolled in an investigational drug trial or medical device investigation within four weeks of enrolment.
  • Participant has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation.
  • Participant has a history of cancer in the pelvic region, are currently receiving cancer treatment, or has received radiation therapy in the pelvic region.
  • Participant has addictive behaviour defined as the abuse of alcohol, cannabis, opioids, or other intoxicating drugs.
  • Participant does not speak or understand Danish.
  • The following contraception is considered effective: Intrauterine device, hormonal contraceptives such as birth control pills, implants, contraceptive patch, vaginal ring, and contraceptive injection.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEUCon-Bar

The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for either 4 weeks or 12 weeks using UCon with the Bar electrode


Locations(3)

Aarhus University Hospital

Aarhus, Denmark

Herlev Hospital

Herlev, Denmark

Odense University Hospital

Odense, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06091566


Related Trials